AR022318A1 - Utilizacion de imidazo[1,5-a]-pirido [3,2-e]-pirazinonas como inhibidores de la fosfodiesterasa 5 para tratar la disfuncion erectil, como inhibidoresduales de la fosfodiesterasa 3 y de la fosfodiesterasa 5 para tratar la insuficiencia cardiaca, hipertonia pulmonar y angiopatias, que estan acompanada - Google Patents

Utilizacion de imidazo[1,5-a]-pirido [3,2-e]-pirazinonas como inhibidores de la fosfodiesterasa 5 para tratar la disfuncion erectil, como inhibidoresduales de la fosfodiesterasa 3 y de la fosfodiesterasa 5 para tratar la insuficiencia cardiaca, hipertonia pulmonar y angiopatias, que estan acompanada

Info

Publication number
AR022318A1
AR022318A1 ARP000100246A ARP000100246A AR022318A1 AR 022318 A1 AR022318 A1 AR 022318A1 AR P000100246 A ARP000100246 A AR P000100246A AR P000100246 A ARP000100246 A AR P000100246A AR 022318 A1 AR022318 A1 AR 022318A1
Authority
AR
Argentina
Prior art keywords
14aryl
alkyl
several times
inhibitors
phosphodiesterase
Prior art date
Application number
ARP000100246A
Other languages
English (en)
Spanish (es)
Original Assignee
Dresden Arzneimittel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999102082 external-priority patent/DE19902082A1/de
Priority claimed from DE1999161302 external-priority patent/DE19961302A1/de
Application filed by Dresden Arzneimittel filed Critical Dresden Arzneimittel
Publication of AR022318A1 publication Critical patent/AR022318A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ARP000100246A 1999-01-20 2000-01-19 Utilizacion de imidazo[1,5-a]-pirido [3,2-e]-pirazinonas como inhibidores de la fosfodiesterasa 5 para tratar la disfuncion erectil, como inhibidoresduales de la fosfodiesterasa 3 y de la fosfodiesterasa 5 para tratar la insuficiencia cardiaca, hipertonia pulmonar y angiopatias, que estan acompanada AR022318A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1999102082 DE19902082A1 (de) 1999-01-20 1999-01-20 Verwendung von Imidazo[1,5-a]-pyrido[3,2-e]-pyrazinonen als Inhibitoren der Phosphodiesterase 5 zur Therapie von erectiler Dysfunktion und Verfahren zu deren Herstellung
DE1999161302 DE19961302A1 (de) 1999-12-18 1999-12-18 Verwendung von Imidazo(1,5-a)-pyrido(3,2-e)-pyrazinonen als duale Inhibitoren der Phosphodiesterase 5 und der Phosphodiesterase 3 zur Therapie der Herzinsuffizienz, von pulmonaler Hypertonie und Gefäßerkrankungen, die mit einer Minderdurchblutung einhergehen

Publications (1)

Publication Number Publication Date
AR022318A1 true AR022318A1 (es) 2002-09-04

Family

ID=26051406

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000100246A AR022318A1 (es) 1999-01-20 2000-01-19 Utilizacion de imidazo[1,5-a]-pirido [3,2-e]-pirazinonas como inhibidores de la fosfodiesterasa 5 para tratar la disfuncion erectil, como inhibidoresduales de la fosfodiesterasa 3 y de la fosfodiesterasa 5 para tratar la insuficiencia cardiaca, hipertonia pulmonar y angiopatias, que estan acompanada

Country Status (23)

Country Link
EP (1) EP1144410A2 (de)
JP (1) JP2002535330A (de)
KR (1) KR20010101603A (de)
CN (1) CN1344268A (de)
AR (1) AR022318A1 (de)
AU (1) AU2291200A (de)
BG (1) BG105714A (de)
BR (1) BR0007613A (de)
CA (1) CA2296224A1 (de)
CO (1) CO5190700A1 (de)
CZ (1) CZ20012627A3 (de)
EA (1) EA200100792A1 (de)
EE (1) EE200100377A (de)
HU (1) HUP0105132A3 (de)
ID (1) ID29790A (de)
IL (1) IL144156A0 (de)
IS (1) IS5987A (de)
LT (1) LT2001078A (de)
LV (1) LV12793B (de)
NO (1) NO20013334L (de)
SK (1) SK10322001A3 (de)
TR (1) TR200102121T2 (de)
WO (1) WO2000043392A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
JP2005513060A (ja) * 2001-12-17 2005-05-12 アルタナ　ファルマ　アクチエンゲゼルシャフト 選択的ｐｄｅ５阻害剤の新規使用
US6916345B2 (en) 2002-02-12 2005-07-12 L'oreal S.A. 6-alkoxy-2,3-diaminopyridine couplers for dyeing keratin fibres
FR2835741B1 (fr) * 2002-02-12 2006-05-05 Oreal Nouveaux coupleurs 6-alcoxy-2,3-diaminopyridine utiles pour la teinture des fibres keratiniques
DE10325813B4 (de) 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
AU2005277384B2 (en) * 2004-08-17 2011-11-17 The Johns Hopkins University PDE5 inhibitor compositions and methods for treating cardiac indications
US8299080B2 (en) 2006-12-13 2012-10-30 Aska Pharmaceutical Co., Ltd. Substituted imidazo[1,5-A] quinoxalines as a PDE9 inhibitor
KR20100110804A (ko) 2007-11-30 2010-10-13 와이어쓰 엘엘씨 포스포디에스테라제 10의 저해물질로서의 아릴 및 헤테로아릴 융합된 이미다조[1,5-ａ]피라진
WO2009070583A1 (en) * 2007-11-30 2009-06-04 Wyeth Pyrido[3,2-e]pyrazines, process for preparing the same, and their use as inhibitors of phosphodiesterase 10
EP3121178B1 (de) * 2011-10-10 2018-09-19 H. Lundbeck A/S 6-[4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one als pde9 inhibitor
WO2013110768A1 (en) 2012-01-26 2013-08-01 H. Lundbeck A/S Pde9 inhibitors with imidazo triazinone backbone
JP5842640B2 (ja) * 2012-01-31 2016-01-13 株式会社東洋新薬 ホスホジエステラーゼ３阻害剤
WO2016022836A1 (en) * 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Organic compounds
US9938284B2 (en) 2014-08-07 2018-04-10 Intra-Cellular Therapies, Inc. Organic compounds
CN107810187B (zh) 2015-07-07 2020-09-15 H.隆德贝克有限公司 用于治疗外周疾病的具有咪唑并三嗪酮骨架和咪唑并吡嗪酮骨架的pde9抑制剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055465A (en) * 1989-05-31 1991-10-08 Berlex Laboratories, Inc. Imidazoquinoxalinones, their aza analogs and process for their preparation
DE19510965A1 (de) * 1995-03-24 1996-09-26 Asta Medica Ag Neue Pyrido/3,2-e/pyrazinone mit antiasthmatischer Wirksamkeit und Verfahren zu deren Herstellung

Also Published As

Publication number Publication date
KR20010101603A (ko) 2001-11-14
CZ20012627A3 (cs) 2002-01-16
CA2296224A1 (en) 2000-07-20
TR200102121T2 (tr) 2002-01-21
WO2000043392A3 (de) 2000-09-28
SK10322001A3 (sk) 2002-07-02
ID29790A (id) 2001-10-11
HUP0105132A2 (hu) 2002-05-29
AU2291200A (en) 2000-08-07
IS5987A (is) 2001-06-29
IL144156A0 (en) 2002-05-23
CO5190700A1 (es) 2002-08-29
JP2002535330A (ja) 2002-10-22
LV12793A (lv) 2002-02-20
BG105714A (en) 2002-02-28
HUP0105132A3 (en) 2002-12-28
LV12793B (lv) 2002-05-20
EA200100792A1 (ru) 2002-10-31
CN1344268A (zh) 2002-04-10
EP1144410A2 (de) 2001-10-17
NO20013334D0 (no) 2001-07-05
LT2001078A (en) 2002-08-26
BR0007613A (pt) 2001-10-30
NO20013334L (no) 2001-07-05
WO2000043392A2 (de) 2000-07-27
EE200100377A (et) 2002-10-15

Similar Documents

Publication Publication Date Title
AR022318A1 (es) Utilizacion de imidazo[1,5-a]-pirido [3,2-e]-pirazinonas como inhibidores de la fosfodiesterasa 5 para tratar la disfuncion erectil, como inhibidoresduales de la fosfodiesterasa 3 y de la fosfodiesterasa 5 para tratar la insuficiencia cardiaca, hipertonia pulmonar y angiopatias, que estan acompanada
GT200000168A (es) Compuestos farmaceuticamente activos.
GT200000069A (es) Derivados heterociclicos utiles como agentes anticancerosos.
PE20120121A1 (es) Derivados de imidazopirazina como inhibidores de syk
AR094185A2 (es) Sal de acido fosforico de un inhibidor de la dipeptidil peptidasa-iv
MY128479A (en) (beta)-carboline derivatives useful as inhibitors of phosphodiesterase
MX9307940A (es) Nuevos derivados de la imidazopiridina, proceso para su preparacion y formulaciones farmaceuticas que los incluyen
PE20040897A1 (es) 8-[3-amino-piperidin-1-il]-xantinas y su preparacion como medicamentos
EP2156864A3 (de) Haarfärbemittel enthaltend unlösliche Bestandteile und ihre Verwendungen
MX9203369A (es) Derivados de imidazo [1,5-a] piridina y composiciones farmaceuticas que los contienen.
DE50302975D1 (de) Neue xanthinderivate, deren herstellung und deren verwendung als arzneimittel
SV2003001173A (es) 1-alquil o 1-cicloalquil-triazolo [4,3-a] quinazolin-5- onas como inhibidoras de fosfodiesterasa
NO992808D0 (no) Anvendelse av gr°nne porfyriner for fremstilling av et medikament for behandling av sekundµre katarakter
BR0006380A (pt) Derivados de 2-aminoalquil-1,4-diamino-benzeno e agentes de tingimento contendo estes compostos
PE20030208A1 (es) Derivados de indirubina que contienen azufre, su preparacion y uso
PE20030664A1 (es) DERIVADOS DE TRIAZOLO [4,3-a]PIRIDO[2,3-d]PIRIMIDIN-5-ONA, COMPOSICIONES QUE LOS CONTIENEN, METODO DE PREPARACION Y USO
BR0109163A (pt) Uso de pirido[3,2-e]-pirazinonas como inibidores da fosfodieterase 5, para terapia de disfunção erétil
TR199902495T2 (xx) Bile�imler.
ES2175386T3 (es) Derivados de 2,3-benzodiazepina y su utilizacion como inhibidores de receptores de ampa.
Xia et al. Synthesis and phosphodiesterase 5 inhibitory activity of novel pyrido [1, 2-e] purin-4 (3H)-one derivatives
CA2445625A1 (en) Pyrazino'1',2':1,6!pyrido'3,4-b!indole1,4-dione derivatives
ES2059931T3 (es) Procedimiento para el tratamiento de la hipertrofia e hiperplasia cardiaca asi como vascular.
MXPA03008250A (es) Nuevos derivados de diaminopirazol y colorantes que contienen estos compuestos.
AR015518A1 (es) Uso de derivados de tiadiazolo piridina para la produccion de un medicamento para el tratamiento de enfermedades que se modulan mediante la inhibicion delas fosfodiesterase(s)
MX9306563A (es) Derivados de imidazopiridinas, proceso para su preparacion y formulaciones farmaceuticas que los contienen.